Violation Tracker Parent Company Summary
Parent Company Name:
Novartis
Ownership Structure:
publicly traded (ticker symbol NVS)
Headquartered in:
Switzerland
Major Industry:
pharmaceuticals
Specific Industry:
pharmaceuticals
Penalty total since 2000:
$2,526,283,570
Number of records:
39
| Top 5 Offense Groups (Groups Defined) | Penalty Total | Number of Records |
|---|---|---|
| competition-related offenses | $1,090,950,000 | 10 |
| government-contracting-related offenses | $638,474,307 | 11 |
| healthcare-related offenses | $514,508,250 | 7 |
| employment-related offenses | $282,061,595 | 5 |
| financial offenses | $168,500 | 1 |
| Top 5 Primary Offense Types | Penalty Total | Number of Records |
|---|---|---|
| False Claims Act and related | $638,474,307 | 11 |
| kickbacks and bribery | $504,800,000 | 4 |
| off-label or unapproved promotion of medical products | $501,638,250 | 5 |
| Foreign Corrupt Practices Act | $370,800,000 | 3 |
| price-fixing or anti-competitive practices | $215,350,000 | 3 |
Notes:
Parent-subsidiary linkages are based on relationships current as of the latest revision listed in the Update Log, which may vary from what was the case when a violation occurred. The penalty totals are adjusted to account for the fact that the individual entries below may include both agency records and settlement announcements for the same case; or else a penalty covering multiple locations may be listed in the individual records for each of the facilities. The totals are also adjusted to reflect cases in which federal and state or local agencies cooperated and issued separate announcements of the outcome. Duplicate or overlapping penalty amounts are marked with an asterisk in the list below.
Links:
For an overview of this company's accountability track record, read its Corporate Rap Sheet here.
For more details on misconduct by this company, see its entry in the Project On Government Oversight's Federal Contractor Misconduct Database.
Subsidy Tracker data on financial assistance to this company by federal, state and local government agencies can be found here.
For an overview of assistance this company is receiving under the CARES Act, see its Covid Stimulus Watch summary page here.
Individual Penalty Records:
Click on the company or penalty amount for more information on each case.
| Company | Primary Offense Type |
Year |
Agency | Penalty Amount |
|---|---|---|---|---|
| CIBA Vision | price-fixing or anti-competitive practices | 2000 | MULTI-AG | $5,000,000 |
| CHIRON CORPORATION | workplace safety or health violation | 2000 | OSHA | $90,140 |
| NOVARTIS PRODUCTS | environmental violation | 2000 | EPA | $13,200 |
| NOVARTIS CONSUMER HEALTH, INC. | environmental violation | 2000 | EPA | $5,000 |
| Chiron Corporation Ltd | economic sanction violation | 2004 | OFAC | $168,500 |
| Geneva Pharmaceuticals | price-fixing or anti-competitive practices | 2005 | MULTI-AG | $15,350,000 |
| NOVARTIS PHARMACEUTICALS CORPORATION | benefit plan administrator violation | 2006 | EBSA | $10,001 |
| Novartis Animal Health US, Inc. | environmental violation | 2006 | EPA | $6,500 |
| Sandoz | False Claims Act and related | 2009 | KY-AG | $16,000,000 |
| Novartis Pharmaceuticals Corporation | off-label or unapproved promotion of medical products | 2010 | FDA | $422,500,000 |
| Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | off-label or unapproved promotion of medical products | 2010 | FDA | $72,500,000 |
| Eon Labs Inc. | False Claims Act and related | 2010 | DOJ_CIVIL | $3,500,000 |
| Novartis Corporation | employment discrimination | 2010 | private lawsuit-federal | $175,000,000 |
| Novartis Pharmaceuticals Corporation | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*) $88,258,694 |
| Novartis Pharmaceuticals Corporation | False Claims Act and related | 2010 | HI-AG | $3,333,333 |
| Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*) $29,000,000 |
| Sandoz Inc. | False Claims Act and related | 2010 | ID-AG | $1,650,000 |
| Sandoz, Inc. | HHS civil monetary penalties | 2011 | HHSOIG | $230,000 |
| Sandoz, Inc. | False Claims Act and related | 2011 | MS-AG | $30,110,618 |
| Novartis | wage and hour violation | 2012 | private lawsuit-federal | $99,000,000 |
| Novartis Pharmaceuticals Corp. | False Claims Act and related | 2012 | KY-AG | $2,750,000 |
| Novartis Pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | TX-AG | $6,638,250 |
| Novartis Pharmaceuticals | employment discrimination | 2013 | OFCCP | $51,594 |
| Novartis | False Claims Act and related | 2013 | LA-AG | $7,000,000 |
| Novartis Pharmaceuticals Corp. | False Claims Act and related | 2013 | ID-AG | $750,000 |
| Sandoz | False Claims Act and related | 2013 | LA-AG | $13,100,000 |
| NOVARTIS CONSUMER HEALTH INC. | workplace safety or health violation | 2013 | OSHA | $6,078 |
| Novartis Pharmaceuticals | kickbacks and bribery | 2015 | USAO | $390,000,000 |
| Sandoz, Inc. | HHS civil monetary penalties | 2015 | HHSOIG | $12,640,000 |
| Novartis Pharmaceuticals Corporation | kickbacks and bribery | 2015 | MULTI-AG | (*) $83,129,754 |
| Novartis AG | Foreign Corrupt Practices Act | 2016 | SEC | $25,000,000 |
| Novartis Corporation and Alcon Laboratories | employment discrimination | 2016 | private lawsuit-federal | $8,000,000 |
| Novartis Pharmaceuticals | False Claims Act and related | 2019 | IL-AG | $21,280,356 |
| Sandoz Inc. | price-fixing or anti-competitive practices | 2020 | DOJ_ANTITRUST | $195,000,000 |
| Novartis Pharmaceuticals Corporation | kickbacks and bribery | 2020 | CA-AG | $11,800,000 |
| Novartis Pharmaceuticals Corporation | False Claims Act and related | 2020 | DOJ_CIVIL | (*) $642,000,000 |
| Novartis Hellas S.A.C.I. et al. | Foreign Corrupt Practices Act | 2020 | DOJ_CRIMINAL | $233,000,000 |
| Novartis Pharmaceuticals Corp. | kickbacks and bribery | 2020 | MULTI-AG | $103,000,000 |
| Novartis AG | Foreign Corrupt Practices Act | 2020 | SEC | $112,800,000 |
